News
Tag: Financial & Investor News
-
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025. Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025. SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and…
-
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
SEATTLE and VANCOUVER, British Columbia, May 6, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate…
-
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
SEATTLE and VANCOUVER, British Columbia, March 6, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and provide…
-
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025. Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025. SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization…
-
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
SEATTLE and VANCOUVER, British Columbia, March 7, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will be presenting at the Barclays 27th Annual Global Healthcare…